Soap and Cleaning Compound Manufacturing (U.S.) — An Investor's Primer

NAICS 2022 code 32561. NAICS is the North American Industry Classification System, the U.S. federal standard for sorting businesses into industries. This is a five-digit "industry" that rolls up three more detailed six-digit industries: 325611, 325612, and 325613.

1. Overview

This is the industry that makes the things that clean — and the chemistry that makes cleaning possible. It bundles together three related but economically distinct businesses: the makers of finished soaps and detergents (Tide, Dawn, Dove, Palmolive), the makers of polishes, disinfectants, and other sanitation goods (Lysol, Clorox wipes, Pine-Sol, Glade, Armor All), and the bulk chemical producers who make the surfactants — the active cleaning molecules — that go into all of the above.

Read together, they form a supply chain stacked inside one federal code: surfactant plants sell to detergent and cleaner formulators, who sell branded bottles to retailers and institutions. In 2022 the whole group shipped about $45.8 billion of product from U.S. plants and employed roughly 57,000 people.[1][2]

For investors the headline is the same across all three: there is no pure-play, publicly traded U.S. "soap and cleaning" company. The consumer end is dominated by a handful of giant, diversified consumer-goods multinationals for whom this is one segment among many; the chemical end has exactly one U.S.-listed pure play; and the most category-focused owners — private-label makers, artisan brands, family firms, specialty chemical producers — are overwhelmingly private or private-equity-owned. So the real story, and this primer's job, is the contrast across the three children: they differ sharply in size, growth, concentration, ownership, and how you would actually invest.

2. What's inside — the three child industries and how they differ

The five-digit code contains three six-digit industries. They sit in sequence along a value chain — raw chemistry (325613) → finished cleaning products (325611 and 325612) — and they could hardly be more different as businesses.

CR4 = the share of industry revenue held by the four largest firms (a "concentration ratio"); HHI = Herfindahl-Hirschman Index, the standard single-number concentration gauge (suppressed by the Census Bureau for 325611 and 325613); B2B = business-to-business; ETF = exchange-traded fund. Figures from the child primers and federal sources.[1][2][3][4][5]

The three contrasts that matter most:

1. Size and growth run in opposite directions from concentration. Soap & detergent is by far the biggest slice (~three-fifths of the level) but the slowest-growing — a defensive, cash-generative staple whose volumes barely beat population growth.[3] Polish & sanitation is the smallest by revenue yet the most jobs-intensive, and its recent numbers are the noisiest because the 2020–21 pandemic drove a once-in-a-generation cleaning spike followed by a multi-year hangover.[4] Surfactants is the middle child by revenue but a different animal entirely — a capital-heavy B2B chemical business whose defensive consumer-staples core is bolted to cyclical farm, oil, and construction demand.[5]

2. Ownership mix flips as you move up the chain. At the consumer end (325611 and 325612) the shelf is a branded oligopoly — Procter & Gamble, Colgate-Palmolive, Church & Dwight, Clorox, Reckitt, Unilever, plus family-owned S.C. Johnson — but the manufacturing census is much more fragmented, because a long tail of artisan soap makers, contract packagers ("co-packers"), and private-label producers fills out the plant count.[3][4] At the chemical end (325613) there are no artisans: it is a small club of merchant producers (Stepan), integrated majors (Dow, BASF, Indorama), and captive in-house producers.[5]

3. The investable route differs by child. For soap/detergent and polish/sanitation, public investors buy diversified staples companies and get cleaning exposure as a slice; the focused opportunities (contract manufacturers, artisan and family brands, PE roll-ups) are private.[3][4] For surfactants there is a single listed pure play, Stepan, and everything else is diluted-major or private.[5] There is no ETF for any of the three individually.

3. How big it is (the level rollup)

Federal ground-truth figures for the whole five-digit industry (U.S. establishments only):

The Economic Census is the once-every-five-years full count of U.S. businesses; County Business Patterns (CBP) is the Census Bureau's annual establishment-and-employment series.

How the children add up. The three six-digit industries tie out almost exactly to this level: establishments (845 + 455 + 106 = 1,406) and employment (33,783 + 17,230 + 6,174 = 57,187) match to the person, and receipts sum to ~$45.87 billion against the level's $45.83 billion.[3][4][5] Firm counts do not add up the same way (742 + 421 + 108 = 1,271 versus 1,252 at the level) because a single company can operate in more than one of the child industries and is counted once at the rollup — a normal feature of how the Census aggregates, not an error.

Concentration — and why the level looks tamer than its parts. For the industry as a whole:

An HHI of ~652 sits in "unconcentrated" territory under the federal antitrust yardstick (broadly, below ~1,000–1,500).[1] But that aggregate is misleading if read alone: it blends a highly concentrated soap/detergent business (where the top four firms hold ~60% of revenue), a fragmented polish/sanitation business (top four ~25%, HHI ~252), and a surfactant business that is concentrated at the very top (top four ~63%, top twenty ~90%).[3][4][5] The level number is moderate precisely because averaging three unlike structures washes out the extremes — a caution against treating the five-digit HHI as a description of any real competitive arena.

Undercount and interpretation caveats:

1. These are U.S. factory-gate shipments, not U.S. consumption. The $45.8 billion measures what domestic plants ship; it excludes imported finished soap, cleaners, and surfactant, and it is not retail spending. It also is not any one company's size: Procter & Gamble's global Fabric & Home Care segment alone did roughly $29.6 billion worldwide in fiscal 2025 — more than half the entire U.S. industry's shipments — because most of that is made and sold abroad.[3][6]
2. The plant count understates how many businesses "make soap." CBP counts only employer establishments. The thousands of hobbyist and artisan soap makers with no paid employees are "nonemployer" businesses outside the 1,406 count — economically tiny, but a real undercount of participants at the craft end of 325611.[3]
3. Surfactant volume is undercounted too, for a different reason. The Census books each plant to its primary product, so surfactant made captively inside a detergent or petrochemical complex is often recorded elsewhere. The 325613 figure is best read as the merchant-plus-dedicated-plant surfactant industry, not every pound made in the country.[5]

4. The investable universe — where value concentrates

There is no pure play at this level, and value concentrates differently in each child. The map below draws the exposures together; tickers and scale are reserved here and in Section 10.

The consumer end (325611 + 325612) — value sits inside diversified staples giants. The same handful of names appears in both child industries because their portfolios straddle soap, detergent, and cleaning:

Foreign-listed owners of major U.S. brands — Unilever (Dove, Seventh Generation), Reckitt (Lysol; a 30% retained interest in Essential Home brands Air Wick, Resolve, Easy-Off following divestment to Advent International in 2025), Henkel (Persil, Purex, Dial), Kao — are reachable mainly via ADRs (American Depositary Receipts, foreign shares traded on U.S. markets).[3][4]

The chemical end (325613) — one listed pure play. Stepan Company (NYSE: SCL, ~$1.1B market value, ~$2.2B 2024 sales, surfactants ~three-fifths of sales) is the only way to own the surfactant industry directly on a U.S. exchange; Dow (DOW) and Innospec (IOSP) give diluted exposure, as do foreign majors BASF, Evonik, Croda, Clariant, and Indorama Ventures.[5]

Where the focused value is private:

• Family / private consumer owners: S.C. Johnson (Windex, Pledge, Glade, Scrubbing Bubbles; ~$11.8B revenue), Turtle Wax (car care), Dr. Bronner's (castile soap).[4][3][7]
• Private-equity roll-ups: PurposeBuilt Brands (Weiman, Goo Gone, Green Gobbler; owned by Rock Mountain Capital and The Olayan Group), KIK Consumer Products (Comet, Spic and Span, bleach and contract cleaning), and institutional consolidators Solenis/Diversey and Zep.[4]
• Private surfactant specialists: Nouryon (Carlyle/GIC-owned), Pilot Chemical, Colonial Chemical, plus venture-backed biosurfactant developers.[5]
• Contract and private-label manufacturers across both consumer children — e.g., First Quality, which bought Henkel's North American private-label detergent business in 2025.[3]

Bottom line for allocators: public money buys diversified, defensive baskets; anyone wanting a concentrated bet on cleaning manufacturing itself — branded, private-label, or chemical — is looking at private companies (with Stepan the lone listed exception at the chemical end).

5. How the money works

All three children make money the way branded consumer-and-specialty manufacturers do — units sold × price, minus the cost of goods and the marketing needed to move them — but the balance of levers shifts as you move up the chain.

• Volume × price, with pricing power from brands (strongest at the consumer end). Branded leaders in soap, detergent, and cleaners can raise prices and hold shoppers because of brand trust and shelf presence, earning far higher margins than the private-label and contract makers who compete almost entirely on cost.[3][4] For disinfectants the brand is also a safety claim, which reinforces pricing power.[4] Surfactant makers, selling chemistry to industrial buyers, have less brand pricing power and lean on specialty mix instead.[5]
• The input-cost spread is the swing factor everywhere. The shared raw materials are surfactants and their feedstocks — petrochemical (ethylene oxide, linear alkylbenzene) and oleochemical (palm, palm-kernel, and coconut oils) — plus fragrances, packaging resin, and energy.[3][5] Because volumes barely grow, quarterly earnings across all three are driven mostly by the gap between selling prices and input costs, and producers pass raw-material moves through with a lag, so margins compress when inputs spike and widen when they fall.[5]
• Capital intensity rises up the chain. Detergent and cleaner blending plants are relatively cheap and low-capital; the economics turn on brand, distribution, and working capital.[4] Surfactant plants are the opposite — expensive, continuous-process, and most profitable when run full, so capacity utilization and fixed-cost leverage dominate: when Stepan's Millsdale, Illinois complex had operational problems and lower volumes in 2024, earnings fell directly.[5] This is why revenue per worker ranges from ~$0.5M in polish/sanitation to ~$1.7M in surfactants.
• Marketing is the moat at the consumer end. Advertising plus "trade spend" (payments to retailers for shelf space and promotion) is among the biggest line items for branded players — the spend that sustains pricing power, but also a chunk of every sales dollar reinvested just to hold share.[3][4]
• Recurring "razor-and-blade" and toll models at the edges. Institutional-hygiene players (Ecolab, Diversey, Zep) place dispensing systems on-site and sell concentrated refills on contract — stickier, service-like revenue.[4] Surfactant makers similarly run customers' recipes on a conversion-fee ("toll") basis, earning a margin without taking feedstock risk.[5]

Net: a defensive, cash-generative, low-growth group where the winners compound through brand pricing (consumer end) or through running capital-intensive plants full and managing the feedstock spread (chemical end).

6. What drives demand

• Households and population — the shared baseline. All three children ultimately track the number of households doing laundry, dishes, and cleaning. That grows slowly and steadily, which is why the whole group is defensive but not fast-growing.[3][5]
• Hygiene awareness and health scares. Demand spikes around health events — hand soap, sanitizer, and disinfectant volumes surged in 2020–21, then normalized as buyers destocked. The pandemic left a higher structural cleaning baseline (most visible in 325612) but no repeat spike.[4]
• Away-from-home activity. Institutional and industrial cleaning (restaurants, hotels, hospitals, food processing) rises and falls with travel, dining, and infection-control standards — the more cyclical demand base for Ecolab-type players.[4]
• Trade-down and trade-up cycles. When inflation bites, shoppers shift to private label and value brands; when incomes are healthy, they trade up to premium pods, scents, and eco formats. This mix shift moves profitability more than total volume does.[3][4]
• Cyclical end markets — unique to surfactants. A meaningful slice of surfactant demand feeds agriculture (crop-chemical adjuvants), oilfield (drilling and recovery), and construction (concrete, coatings) — cyclical drivers that were soft in 2024 but stronger in 2025, and that amplify the group's swings beyond the steady consumer core.[5]
• Sustainability and premiumization. Concentrates, refills, plastic reduction, plant-based formulas, and — at the chemical end — bio-based and fermentation-made surfactants are reshaping product lines and pulling value toward higher-margin specialty chemistry.[4][5]

7. Regulation

Because the three children span personal-care-adjacent products, health-claim products, and industrial chemicals, they draw on overlapping but differently-weighted regulators. Direction of travel across all three is tighter ingredient scrutiny, more disclosure, and sustainability/packaging pressure — a rising compliance cost that the large players can absorb more easily than small ones.

• EPA (Environmental Protection Agency). The Toxic Substances Control Act (TSCA, the federal chemical-safety law) governs ingredients across all three; the EPA's voluntary Safer Choice label is a marketing edge for greener soaps and cleaners.[3] Crucially for 325612, disinfectants and sanitizers are legally antimicrobial pesticides and must be registered under FIFRA (the Federal Insecticide, Fungicide, and Rodenticide Act) with efficacy data before any public-health claim ("kills SARS-CoV-2") can appear — a costly, slow process that is both a compliance burden and a competitive barrier.[4]
• 1,4-dioxane — the cross-cutting chemistry issue. This trace contaminant forms during ethoxylation, the reaction used to make many surfactants, so it links the chemical child to the consumer ones. In November 2024 the EPA finalized an "unreasonable risk to human health" determination on 1,4-dioxane and specifically included byproduct exposure from ethoxylation in the evaluated conditions of use — a forward-looking overhang that could require producers to further purify ethoxylated surfactants.[5] New York caps household cleaning and personal-care products at ≤1 part per million, with all waivers having expired on December 30, 2025; California's Safer Consumer Products program moved in 2026 to list high-dioxane dish detergents and shampoos as "Priority Products."[3][5]
• FDA (Food and Drug Administration). Soaps making antibacterial/drug claims and hand sanitizers are regulated as over-the-counter drugs; the FDA's 2016 rule (effective September 2017) barred 19 antibacterial ingredients, including triclosan, from consumer antiseptic washes, forcing broad reformulation.[3]
• Phosphate and VOC rules. State bans pushed manufacturers to reformulate automatic-dishwasher detergents phosphate-free nationwide by 2010; state VOC (volatile organic compound) limits constrain aerosols and air fresheners.[3][4]
• Product safety and disclosure. The Consumer Product Safety Commission oversees child-resistant packaging (tightened after laundry-pod ingestion incidents); OSHA and DOT govern workplace chemical handling and flammable-aerosol transport; and California/New York "right to know" laws require ingredient disclosure.[3][4]

8. Consolidation

The whole group is a branded oligopoly resting on a fragmented base, and consolidation has run steadily across all three children — but in different forms.

• Soap & detergent (325611): stable oligopoly with portfolio pruning. P&G leads U.S. laundry decisively (Tide, Gain) with more than 50% of retail share in the liquid, unit-dose, and powder categories, followed by Church & Dwight, Henkel, and Unilever.[3] The recent motion is de-consolidation of the thin-margin end: Henkel closed the sale of its North American private-label detergent business (~€500M) to First Quality in 2025 — the majors would rather cede low-margin store-brand volume than defend it.[3]
• Polish & sanitation (325612): a private-equity roll-up playground. The top five (P&G, Church & Dwight, Clorox, Reckitt, S.C. Johnson) hold ~55% of North American cleaning products, but below them PE has assembled specialty portfolios (PurposeBuilt Brands out of Weiman and a string of niche brands, now owned by Rock Mountain Capital and The Olayan Group) and institutional cleaning has consolidated (Solenis's $4.6 billion purchase of Diversey in 2023).[4] At the end of 2025, Reckitt completed the sale of a majority interest in Essential Home (Air Wick, Cillit Bang, Resolve, Easy-Off) to Advent International, retaining a 30% equity stake.[4]
• Surfactants (325613): cross-border and PE-driven, with the highest top-end concentration. The defining deal was Thailand's Indorama Ventures buying Huntsman's surfactants business for ~$2 billion in 2020, taking over major U.S. Gulf Coast plants and removing a domestic producer's name from the field.[5] In 2023 South Korea's Samyang Holdings acquired Verdant Specialty Solutions (amphoteric surfactants) for ~$250 million.[5] Merchants like Stepan respond by integrating backward — its $220 million, 75,000-ton-per-year Pasadena, Texas alkoxylation plant started up in April 2025.[5]

Barriers to entry are high at the branded and chemical tiers — brand equity, national advertising, retailer shelf access, EPA registration, R&D (research and development), and capital-intensive plants — but low at the commodity/private-label end, where a contract manufacturer plus a retailer relationship is enough to compete on price. That split is exactly why the level's concentration reads as merely moderate.

9. Risks

• Input-cost volatility (shared). Surfactants, oleochemicals/palm oil, packaging resin, and energy swing with commodity and oil markets; when costs jump faster than prices can follow, the margin spread compresses across all three children.[3][5]
• Private-label trade-down (consumer end). In downturns shoppers shift to cheaper store brands, pressuring branded volumes and mix in 325611 and 325612.[3][4]
• Retailer power (consumer end). A few enormous retailers (Walmart, Amazon, Costco, dollar chains) control shelf access and dictate price and promotion terms.[4]
• Demand normalization (especially 325612). The pandemic hygiene surge reversed into a multi-year destocking hangover — cleaning-wipe sales fell more than 25% in the year to September 2022 — a reminder that spikes reverse.[3][4]
• Cyclical and operating-leverage risk (chemical end). Surfactants' farm/oil/construction exposure amplifies downturns, and because plant costs are heavily fixed, an outage or soft volumes hit earnings hard (Stepan, 2024).[5]
• Regulatory and litigation exposure (shared). Ingredient bans (triclosan-style), FIFRA registration cost, 1,4-dioxane and PFAS scrutiny, VOC limits, sustainability/packaging mandates, and product-safety issues all raise cost and legal risk.[3][4][5]
• ESG and reputational pressure. Palm-oil deforestation, single-use plastic, aerosol/benzene recalls, and "greenwashing" claims draw activist and regulatory attention; operational shocks (Clorox's 2023 cyberattack) also bite.[3][4]
• Structurally low growth (shared). These are mature categories; volumes roughly track population, so the group is defensive but offers limited organic top-line growth — and for equity investors, thin public float (one surfactant pure play, no consumer pure play) concentrates risk.

10. How to invest and the outlook

Public-market routes. Because there is no pure play at any level, public investors buy the group as diversified consumer-staples stocks plus one chemical name:

• Broadest consumer exposure: Procter & Gamble (PG), the most direct large-cap across both consumer children; Church & Dwight (CHD), the most laundry-concentrated; Colgate-Palmolive (CL) and Clorox (CLX) for dish, soap, and cleaning; Energizer (ENR) for auto care.[3][4]
• Institutional/away-from-home: Ecolab (ECL) and STERIS (STE).[4]
• The surfactant pure play: Stepan (SCL) — a small-cap merchant producer and 58-year consecutive dividend raiser, the cleanest listed proxy for U.S. surfactant volumes and margins, but carrying single-company operating and feedstock risk.[5]
• Foreign brand owners via ADRs: Unilever, Reckitt, Henkel, Kao.[3][4]
• Index route: broad consumer-staples ETFs (e.g., XLP, VDC) hold the consumer names; there is no dedicated soap/cleaning or surfactant ETF, so the chemical child appears only as a sliver of materials-sector funds.[3][5]

These are generally dividend-oriented, defensive holdings — owned for stability and yield, not rapid appreciation.

Private-market routes. The focused opportunities are private and differ by child: contract and private-label manufacturers and artisan/regional soap brands (325611); family firms (S.C. Johnson, Turtle Wax) and PE roll-ups of cleaning brands (325612); and specialty/biosurfactant producers plus small formulators reachable via the SBA's generous small-business thresholds — 1,100 employees for 325611 and 900 employees for 325612 and 325613.[3][4][5] These give purer exposure to the manufacturing itself and buy-and-build upside, at the cost of illiquidity and single-brand risk. SBA is the U.S. Small Business Administration.

Near-term drivers to watch (forward-looking). Expect low-single-digit volume growth roughly in line with households across the group. The bigger swing factors: the margin spread as post-2022 input-cost inflation eases and pricing normalizes; private-label share, which tends to keep climbing while budgets are tight; premiumization and sustainability (pods, concentrates, refills, plant-based and bio-based formulas) as the main way to lift price per use; volume recovery in the pandemic-distorted cleaning category and in cyclical surfactant end markets; and continued portfolio reshuffling — majors shedding low-margin volume, PE rolling up niche brands, and cross-border consolidation in chemicals. The reasonable base case is a steady, cash-generative, competitively intense industry — attractive for income and defense, modest for growth — with the chemical child (325613) offering the most cyclicality and the only direct listed pure play.

---

Sources

1. U.S. Census Bureau, "2022 Economic Census" (NAICS 32561 receipts $45.83B, firms 1,252, concentration ratios CR4/CR8/CR20/CR50, HHI 651.8), 2022. https://www.census.gov/programs-surveys/economic-census.html
2. U.S. Census Bureau, "County Business Patterns 2023" (NAICS 32561 establishments 1,406, employment 57,187, annual payroll $4.22B), 2023. https://www.census.gov/programs-surveys/cbp.html
3. Histometrics child primer, "Soap and Other Detergent Manufacturing (NAICS 325611)" — synthesizing 2022 Economic Census and 2023 CBP data; P&G Fabric & Home Care segment (~$29.6B FY25); Church & Dwight, Colgate, Clorox results; Henkel/First Quality private-label divestment; FDA triclosan rule; 1,4-dioxane state limits.
4. Histometrics child primer, "Polish and Other Sanitation Good Manufacturing (NAICS 325612)" — 2022 Economic Census and 2023 CBP data; S.C. Johnson (~$11.8B), Turtle Wax, PurposeBuilt Brands ownership, KIK Consumer Products, Solenis/Diversey, Reckitt/Essential Home divestment to Advent International; EPA FIFRA registration; post-pandemic wipe-sales decline; Energizer Auto Care and Ecolab/STERIS exposures.
5. Histometrics child primer, "Surface Active Agent Manufacturing (NAICS 325613)" — 2022 Economic Census and 2023 CBP data; Stepan Company (SCL) scale, Pasadena alkoxylation start-up April 2025, and Millsdale operations; Indorama–Huntsman ($2B, 2020); Samyang–Verdant ($250M, 2023); EPA 1,4-dioxane TSCA action November 2024 and New York limits; biosurfactant trends.
6. Procter & Gamble, "Form 10-K, Fiscal Year 2025 — Fabric & Home Care segment results (~$29.6B)," 2025. https://www.sec.gov/Archives/edgar/data/80424/000008042425000076/pg-20250630.htm
7. Forbes / MatrixBCG, "S.C. Johnson & Son company profile (~$11.8B revenue, 2024; family-owned)," 2024. https://matrixbcg.com/blogs/owners/scjohnson